Posted by Michael Wonder on 07 Jun 2021
America’s wary approval of an Alzheimer’s drug offers hope to millions
7 June 2021 - But its makers still have work to do to prove it can slow the advance of dementia.
News that America’s FDA has granted conditional approval to a new drug, aducanumab, to be marketed as Aduhelm, for the treatment of Alzheimer’s disease, has understandably been greeted as a huge breakthrough.
For millions of people with Alzheimer’s, a remorselessly degenerative illness leading eventually to utter helplessness—and for those caring for them—it is a ray of hope. But the benefits it will offer remain uncertain, and the FDA’s decision is controversial.
